Loading stock data…
Masimo Corporation (MASI)
$179.95
Market Closed
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $403.60M↓ | $412.50M↑ | $371.50M↑ | $370.90M↓ | $372.00M |
| Gross Profit | $250.80M↑ | $247.30M↑ | $230.60M↓ | $233.30M↓ | $234.00M |
| Operating Income | $77.40M↓ | $83.90M↑ | $83.70M↑ | $64.50M↓ | $80.70M |
| Net Income | $57.10M↓ | $68.30M↑ | -$100.40M↓ | $51.30M↑ | -$170.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
44.25
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.67%
Volume
Today's trading volume
3.09M
Recent News
Should Masimo’s Radius VSM Safety Recalls Prompt a Reassessment From Masimo (MASI) Investors?
Earlier in 2026, Masimo voluntarily initiated global Class II recalls of certain Radius VSM ECG assemblies and blood pressure cuffs after identifying risks of false heart-rate alarms and potential skin irritation from rough cuff edges, affecting more than 1,800 devices distributed across the US and multiple international markets. Because these issues touch core patient-monitoring functions that clinicians rely on, the recalls raise meaningful questions about product reliability, regulatory...
Masimo (MASI) Following Recall News Why The Stock Still Looks Fairly Valued
Masimo (MASI) has drawn fresh investor attention after voluntarily recalling specific Radius VSM disposable blood pressure cuffs and ECG pre connected sets, citing possible ECG alarm inaccuracies and skin irritation risks across a globally distributed inventory. See our latest analysis for Masimo. Set against the recent recall headlines, Masimo’s share price return of 41.25% year to date and 2.55% over 90 days suggests investors are still pricing in improving sentiment, even though the 5 year...
Danaher Boosts Product Portfolio With the Acquisition of Masimo
DHR closes its $9.9B Masimo acquisition, adding AI-enabled patient-monitoring and sensor technologies to expand diagnostics solutions.
Danaher Closes Acquisition of Masimo; Maintains Q2, 2026 Outlook
Danaher (DHR) said Wednesday it has completed its acquisition of Masimo (MASI), a speciality diagnos
Wolfe Research Downgrades Danaher Corporation (DHR)
Danaher Corporation (NYSE:DHR) is one of the best healthcare stocks to buy with highest upside potential. Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1 without assigning a price target after assuming coverage of the name. It stated that growth forward and backward is similar, and Thermo Fisher is “a […]